News

Presentation by Jan Törnell of Oncorena and orellanine as treatment for renal cancer

10 October, 2014

The Oncorena company presented at the Park Annual meeting September 2014 by the CEO Jan Tornell. This future treatment is intended for patients with advanced kidney cancer.

Follow us on

Media contact

Sarah Fredriksson

CEO

Telephone:
+46 (0)70 261 4575

Mobile:
+46 (0)70 261 4575

Email:
sarah.fredriksson@pulsinvest.se